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Abstract. Patients with ulcerative colitis (UC) and Crohn's 
disease have an increased risk for developing cancer of the 
colon. Mutations in the K-ras gene are relatively frequent in 
specimens from patients with sporadic colon cancer, but less 
frequent in cases of cancer complicating ulcerative colitis. In 
order to study the problem further we used the polymerase 
chain reaction (PCR) technique followed by a restriction 
fragment length polymorphism (RFLP) assay, to detect 
mutations at codon 12 of K-ras in biopsy specimens from 
patients with UC or Crohn's disease. Six among 27 patients 
(22.2%) with UC and 2 of the 19 patients (10.5%) with 
Crohn's disease examined, carried a mutation at codon 12 of 
K-ras. Our results indicate that mutations in K-ras may be a 
genetic marker that would reveal the predisposition to colon 
cancer among this group of patients. 
Introduction 
Ulcerative colitis (UC) and Crohn's disease are inflammatory 
disorders which predispose patients for the development.of 
colon cancer (1). The risk for the development of cancer is 
20-30 fold elevated in patients with UC for 10-20 years, 
when compared to the general population. Crohn's disease 
exhibits a lower risk, estimated to be about one third of the 
rate found in UC (1,2). 
Histologically, UC is associated with a dysplasia that may 
expand to affect large areas of the mucosa, in which multiple 
aneuploid cell clones coexist. A subpopulation of one of 
these clones has been proposed to give rise to an invasive 
carcinoma ( 1 ). 
Genetic alterations such as ras and p53 mutations, allelic 
loss at loci on chromosomes 5q, 17q and 18q at relatively 
high frequences, have been reported in colon cancer (3). 
Some of these disorders are reported to be related 
etiologically to the promotion of the malignancy. It would be 
very helpful to determine whether some specific genetic 
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alterations are related to the pathogenesis of invasive 
carcinoma in patients with UC or Crohn's disease and map 
the preneoplastic cells in the area of the dysplasia. 
K-ras, Η-ras and N-ras oncogenes are members of the 
ras family of genes. The three genes code for structurally and 
immunologically related proteins of 21 kD, known as ras 
p21. ras p21 is located on the inner side of the plasma 
membrane, possesses GTPse activity and is involved in a 
signal transduction pathway (4). Transforming mutations in 
ras genes are found in about 50% of the human epithelial 
neoplasms and they have a crucial role in the progression of 
the malignancy. 
K-ras mutations are relatively frequent in colon cancer 
and in UC and Crohn's disease they have been reported to 
exist in various frequencies (5-7). The aim of the present 
study was to determine whether K-ras mutations play a role 
in the pathogenesis of invasive carcinoma in UC and Crohn's 
disease. We detected K-ras mutations at codon 12 in 22.2% 
of patients with UC and 10.5% in patients with Crohn's 
disease. 
Materials and methods 
Clinical specimens. Paraffin-embedded tissue sections from 27 
biopsies from ulcerative colitis and 19 from Crohn's disease, 
were obtained from the Department of Gastroenterology of 
the University Hospital, Heraklion, Greece. Lesions with 
dysplasia or cellular atypia are shown in Table I (ulcerative 
colitis) and Table II (Crohn's disease). 
DNA extraction. Three 10 μ thick sections from paraffin-
embedded tissue were put in 1.5 ml Eppendorf tubes and 400 
μΐ digestion buffer containing 100 mM NaCl, 10 mM Tris, 
25 mM EDTA and 0.5% SDS was added. Samples were 
incubated with 100 mg/ml proteinase Κ in 60°C for 1 h and 
then extracted twice with equal volume of phenolxhloroform 
(1:1) and once with chloroform. Supernatants were 
transferred into fresh tubes and DNA was precipitated with 
2.5 volumes of 100% ethanol and 1/20 volume of 5 M NaCl. 
DNA was recovered with centrifugation for 15 min at 4°C, 
washed twice with ice cold 70% ethanol dried and 
resuspended in 20 μΐ distilled water. 
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Table I. Cumulative data for ulcerative colitis. 
Patient 
No. 
1 
2 
3 
4 
5 
6 
7 
S 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
K-rus 
codon 12 
-
-
-
+ 
-
-
+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
+ 
+/+ 
+ 
+ 
mutation 
codon 13 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
High-grade 
dysplasia 
+ 
+ 
+ 
+ 
+ 
+ 
Cellular 
atypia 
+ 
+ 
+ 
+ 
Table II. Cumulative data for Crohn's disease. 
Patient 
No. 
1 
2 
3 
4 
5 
ft 
7 
8 
9 
10 
11 
12 
13 
14 
15 
1ft 
17 
IS 
19 
K-ras mutations 
at codon 12 
-
-
-
-
-
-
-
-
-
-
-
-
-
+ 
-
-
+ 
-
-
High-grade 
dysplasia 
+ 
+ 
+ 
+ 
+ 
Cellular 
atypia 
+ 
+ 
13 were as follows: 5' end primer-5' ACTGAATAT 
AAACTTGTGGTAGTTGGAÇCT3' and 3' end primer-5' 
TCAAAGAATGGTCCTGGACC3' (8). 2 μΐ of the extracted 
DNA of each sample was amplified in a volume of 50 μΐ 
reaction mixture as follows: The reaction solution contained 
35 m M MgCl2, 100 mM Tris HCl pH 8.3, 500 mM KCl, 
0.1% gelatin, 200 μΜ of each dNTP, 500 ng of each primer 
and 1.25 U Taq polymerase (Gibco BRL). Amplification 
parameters were: Denaturation at 94°C for 40 sec, primer 
annealing at 60°C for 45 sec and extention at 72°C for 50 sec, 
increasing the extention time by 1 sec per cycle, up to 40 
cycles. 
RFLP analysis. 10-20 μΐ aliquots of the amplification 
products were digested for 3 h with 20 U BstNl in 60°C for 
codon 12 and another 10-20 μΐ were digested overnight with 
Hph\ in 37°C for codon 13. The enzymes were purchased 
from New England Biolabs. Digestion products were 
electrophoresed through a 2% agarose gel, stained with 
ethidium bromide and photographed on a UV light 
transilluminator. 
Results 
We analyzed 27 specimens from patients with chronic 
ulcerative colitis (UC) and 19 specimens from patients with 
Crohn's disease for the presence of K-ras mutations 
employing a PCR-RFLP analysis. Genomic DNA from the 
colon carcinoma cell line SW480, which is homozygous for a 
codon 12 K-ras mutation, was used as a positive control. Our 
results are summarised in Table I (ulcerative colitis) and 
Table II (Crohn's disease). 
We found 5 heterozygous (patient numbers 4, 7, 24, 26 
and 27) (18.5%) and 1 homozygous (patient number 25) or 
hemizygous (3.7%) mutation in codon 12 of K-ras among 
the 27 specimens from UC and 2 heterozygous (patients 14 
and 17) (10.5%) mutations among the 19 specimens from 
Crohn's disease. 
No correlation was found between K-ras mutations and 
high-grade dysplasia or cellular atypia in either ulcerative 
colitis or Crohn's disease samples, however the number of 
the specimens is low. 
Representative results of the PCR-RFLP analysis are 
shown in Fig. 1 (ulcerative colitis) and Fig. 2 (Crohn's 
disease). 
It is unlikely that the finding of K-ras mutations in our 
study represent PCR artifacts because DNA was extracted 
from various samples independently and the RFLP analysis 
which was positive for the mutations was performed twice 
for each sample. The results were identical on each occasion. 
We also examined 15 specimens from UC for mutations 
in codon 13 of K-ras (8). All the samples tested were 
negative for mutations (see Table I). 
Discussion 
The fact that K-ra.v mutations in colon cancer are a relatively 
frequent genetic event, suggests that these mutations may 
play an important role in the tumorigenic progression of 
dysplasia from UC. The total number of K-ra.v mutations in 
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Figure I. K-ra.v amplification products from ulcerative colitis digested with 
ß.vrNI and electrophoresed through a 2ck agarose gel. M: pUC18/A/aeIII. 
lane 6: undigested PCR product, lane 5: positive control (SW480). lanes 2 
and 4: positive samples, lanes 1 and 3: negative samples, u: uncut, m: mutant, 
n: normal. 
specimens from UC in our study was 6 among 27 specimens 
(22.2%). 
The results obtained from specimen number 25 in which 
only the mutant band for the codon 12 of K-ra.v appeared 
(Fig. 1, lane 2). agrees with previous results that allelic losses 
is a fairly common genetical event in the progression of 
colon malignancy (9). Thus, it seems possible that this 
sample is not homozygous for the mutation but an allelic loss 
occured in its heterozygous previous state which left the 
mutant K-ra.v allele alone, in the cellular DNA. The lack of 
mutations in codon 13 of K-ra.v in 15 specimens of UC 
examined (Table I) shows a preference for codon 12 
mutations of the K-ra.v gene in UC. 
Specimens from patients with Crohn's disease carried K-
ras codon 12 mutations at a lower frequence than UC (2 out 
of 19 specimens) (10.5%). This finding agrees with the 
observation that Crohn's disease exhibits a lower risk for the 
development of colon cancer compared to UC (2). 
We suggest that codon 12 K-ra.v mutations may be 
implicated in the promotion of colon cancer from UC and 
Crohn's disease. Screening patients for K-ra.v mutations 
combined with another genetic marker, such as the p53 onco-
suppressor gene (10-12). may cluster patients with UC and 
Crohn's disease into subpopulations of increased risk for the 
development of colon cancer. 
Furthermore, our results suggest that tumor progression 
between sporadic colon carcinoma and carcinomas arising in 
chronic ulcerative colitis or Crohn's disease may follow a 
different genetic pathway. 
Figure 2. K-ra.v amplification products from Crohn's disease digested with 
ß.vrNl and electrophoresed through a 2'7c agarose gel. M: pUCI8/Wi/elII. 
lane I : undigested PCR product, lane 2: positive control (SW 480). lanes 3. 6. 
7 and 8: negative samples, lanes 4 and 5: positive samples, u: uncut, m: mutant, 
n: normal. 
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